Literature DB >> 19703885

Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.

Tobias Bäuerle1, Jens Hillengass, Kerstin Fechtner, Christian M Zechmann, Lars Grenacher, Thomas M Moehler, Heiss Christiane, Barbara Wagner-Gund, Kai Neben, Hans-Ulrich Kauczor, Hartmut Goldschmidt, Stefan Delorme.   

Abstract

PURPOSE: To examine if standard magnetic resonance (MR) imaging of the axial skeleton is sufficient for evaluation of patients with multiple myeloma (MM) or monoclonal gammopathy of undetermined significance (MGUS) or if whole-body MR is necessary.
MATERIALS AND METHODS: A total of 100 untreated patients with MGUS (n = 27) or any stages of MM (n = 73) were examined with whole-body MR imaging and MR imaging of the axial skeleton. The study was approved by the institutional ethics committee, and written informed consent was given. Spinal pattern ("no diffuse involvement" or "diffuse involvement" as assessed from the signal intensity of the spinal bone marrow), serum parameters, and stage of disease were correlated with the probability of detecting extra-axial lesions with and without destruction of cortical bone by using a multiple logistic regression model.
RESULTS: Of 100 patients, 39 had lesions in the axial skeleton and 37 had lesions in the extra-axial skeleton. Of the latter group, nine patients had no axial lesions and 13 patients had lesions that violated cortical bone, which implied an increased fracture risk. Because of the extraaxial location, lesions in these patients could be diagnosed with whole-body MR only. In addition, no single or combination of clinical factors observed (stage of disease, serum parameters, and spinal pattern) allowed investigators to identify patients with a significantly increased probability of having extra-axial lesions or lesions violating cortical bone.
CONCLUSION: Whole-body MR imaging has potential for use in the initial work-up of patients with MGUS or MM, since almost one-half of all observed lesions would have been missed by using spinal MR imaging only and clinical parameters could not exclude the presence of extra-axial lesions.

Entities:  

Mesh:

Year:  2009        PMID: 19703885     DOI: 10.1148/radiol.2522081756

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  39 in total

Review 1.  Advanced imaging of skeletal manifestations of systemic mastocytosis.

Authors:  J Fritz; E K Fishman; J A Carrino; M S Horger
Journal:  Skeletal Radiol       Date:  2012-02-26       Impact factor: 2.199

2.  Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.

Authors:  Giuseppe Lucio Cascini; Carmela Falcone; Domenico Console; Antonino Restuccia; Marco Rossi; Antonello Parlati; Oscar Tamburrini
Journal:  Radiol Med       Date:  2013-06-26       Impact factor: 3.469

Review 3.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Authors:  Jo Caers; Nadia Withofs; Jens Hillengass; Paolo Simoni; Elena Zamagni; Roland Hustinx; Yves Beguin
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

4.  Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.

Authors:  J Hillengass; M-A Weber; K Kilk; K Listl; B Wagner-Gund; M Hillengass; T Hielscher; A Farid; K Neben; S Delorme; O Landgren; H Goldschmidt
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

5.  [Multiple myeloma: current recommendations for imaging].

Authors:  J Hillengass; S Delorme
Journal:  Radiologe       Date:  2012-04       Impact factor: 0.635

Review 6.  Diagnostic Advances in Multiple Myeloma.

Authors:  Kevin Barley; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

7.  Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).

Authors:  Cristina Nanni; Elena Zamagni; Annibale Versari; Stephane Chauvie; Andrea Bianchi; Marco Rensi; Marilena Bellò; Ilaria Rambaldi; Andrea Gallamini; Francesca Patriarca; Francesca Gay; Barbara Gamberi; Michele Cavo; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-16       Impact factor: 9.236

Review 8.  Imaging in myeloma with focus on advanced imaging techniques.

Authors:  Tara Barwick; Laure Bretsztajn; Kathryn Wallitt; Dimitri Amiras; Andrea Rockall; Christina Messiou
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

9.  Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.

Authors:  Thorsten Derlin; Kersten Peldschus; Silvia Münster; Peter Bannas; Jochen Herrmann; Thomas Stübig; Christian R Habermann; Gerhard Adam; Nicolaus Kröger; Christoph Weber
Journal:  Eur Radiol       Date:  2012-07-29       Impact factor: 5.315

Review 10.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.